SG11201401648RA - Methods and compositions for neuroprotection - Google Patents
Methods and compositions for neuroprotectionInfo
- Publication number
- SG11201401648RA SG11201401648RA SG11201401648RA SG11201401648RA SG11201401648RA SG 11201401648R A SG11201401648R A SG 11201401648RA SG 11201401648R A SG11201401648R A SG 11201401648RA SG 11201401648R A SG11201401648R A SG 11201401648RA SG 11201401648R A SG11201401648R A SG 11201401648RA
- Authority
- SG
- Singapore
- Prior art keywords
- neuroprotection
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22017—Calpain (3.4.22.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22055—Caspase-2 (3.4.22.55)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
- C12Y306/05002—Small monomeric GTPase (3.6.5.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161554982P | 2011-11-03 | 2011-11-03 | |
| US201261663627P | 2012-06-25 | 2012-06-25 | |
| PCT/US2012/062894 WO2013067076A2 (en) | 2011-11-03 | 2012-11-01 | Methods and compositions for neuroprotection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401648RA true SG11201401648RA (en) | 2014-05-29 |
Family
ID=47436166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401648RA SG11201401648RA (en) | 2011-11-03 | 2012-11-01 | Methods and compositions for neuroprotection |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9422560B2 (en) |
| EP (1) | EP2773758B1 (en) |
| JP (1) | JP6118331B2 (en) |
| KR (1) | KR101970034B1 (en) |
| CN (1) | CN103917647B (en) |
| AU (1) | AU2012332517B9 (en) |
| BR (1) | BR112014010769B1 (en) |
| CA (1) | CA2851296C (en) |
| IL (1) | IL232085B (en) |
| MX (1) | MX356814B (en) |
| SG (1) | SG11201401648RA (en) |
| WO (1) | WO2013067076A2 (en) |
| ZA (1) | ZA201403281B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015089368A2 (en) | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
| SG11202002940QA (en) | 2017-11-01 | 2020-04-29 | Alnylam Pharmaceuticals Inc | Complement component c3 irna compositions and methods of use thereof |
| CA3234636A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (en) | 1971-02-10 | 1977-09-15 | Organon Nv | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
| NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
| NL154599B (en) | 1970-12-28 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (en) | 1972-05-11 | 1983-06-01 | Akzo Nv | METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| EP1695979B1 (en) | 1991-12-24 | 2011-07-06 | Isis Pharmaceuticals, Inc. | Gapped modified oligonucleotides |
| CA2135646A1 (en) | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20050032067A1 (en) | 2002-11-05 | 2005-02-10 | Prakash Thazha P. | Non-phosphorous-linked oligomeric compounds and their use in gene modulation |
| JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AR020078A1 (en) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | METHOD FOR CHANGING THE EXPRESSION OF AN OBJECTIVE GENE IN A PLANT CELL |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (en) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
| NZ513402A (en) | 1999-02-12 | 2003-06-30 | Sankyo Co | Novel nucleosides and oligonucleotide analogues |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| WO2004083430A2 (en) | 2003-03-21 | 2004-09-30 | Santaris Pharma A/S | SHORT INTERFERING RNA (siRNA) ANALOGUES |
| EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
| AP2007003921A0 (en) | 2004-08-16 | 2007-02-28 | Atugen Ag | Therapeutic uses of inhibitors of rtp801 |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
| EP1989307B1 (en) | 2006-02-08 | 2012-08-08 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
| JP2010507387A (en) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | Novel siRNA and method of using the same |
| US7872119B2 (en) | 2007-02-26 | 2011-01-18 | Quark Pharmaceuticals, Inc. | Inhibitors of RTP801 and their use in disease treatment |
| SI2170403T1 (en) | 2007-06-27 | 2014-07-31 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of pro-apoptotic genes |
| BRPI0817605A2 (en) * | 2007-10-03 | 2017-05-09 | Quark Pharmaceuticals Inc | new siren structures |
| EP2242854A4 (en) | 2008-01-15 | 2012-08-15 | Quark Pharmaceuticals Inc | Sirna compounds and methods of use thereof |
| CN102026670A (en) | 2008-03-20 | 2011-04-20 | 夸克医药公司 | Novel siRNA compounds for inhibiting RTP801 |
| US8431692B2 (en) * | 2008-06-06 | 2013-04-30 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| AU2009308380B2 (en) | 2008-10-22 | 2015-05-28 | Suzhou Ribo Life Science Co., Ltd. | Methods for treating eye disorders |
| NZ599237A (en) | 2009-11-26 | 2014-03-28 | Quark Pharmaceuticals Inc | Sirna compounds comprising terminal substitutions |
| WO2011072091A1 (en) * | 2009-12-09 | 2011-06-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| US9045755B2 (en) | 2010-06-24 | 2015-06-02 | Quark Pharmaceuticals, Inc. | Double stranded RNA compounds to RhoA and use thereof |
-
2012
- 2012-11-01 JP JP2014540054A patent/JP6118331B2/en not_active Expired - Fee Related
- 2012-11-01 AU AU2012332517A patent/AU2012332517B9/en not_active Ceased
- 2012-11-01 KR KR1020147010978A patent/KR101970034B1/en active IP Right Grant
- 2012-11-01 BR BR112014010769-6A patent/BR112014010769B1/en not_active IP Right Cessation
- 2012-11-01 WO PCT/US2012/062894 patent/WO2013067076A2/en active Application Filing
- 2012-11-01 US US14/354,596 patent/US9422560B2/en active Active
- 2012-11-01 CA CA2851296A patent/CA2851296C/en active Active
- 2012-11-01 SG SG11201401648RA patent/SG11201401648RA/en unknown
- 2012-11-01 CN CN201280054213.1A patent/CN103917647B/en not_active Expired - Fee Related
- 2012-11-01 EP EP12806730.3A patent/EP2773758B1/en not_active Not-in-force
- 2012-11-01 MX MX2014005424A patent/MX356814B/en active IP Right Grant
-
2014
- 2014-04-10 IL IL232085A patent/IL232085B/en active IP Right Grant
- 2014-05-08 ZA ZA2014/03281A patent/ZA201403281B/en unknown
-
2016
- 2016-08-04 US US15/228,174 patent/US9738896B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2773758B1 (en) | 2017-06-07 |
| MX2014005424A (en) | 2014-10-17 |
| KR101970034B1 (en) | 2019-04-17 |
| US20150031746A1 (en) | 2015-01-29 |
| CN103917647B (en) | 2020-07-10 |
| US9422560B2 (en) | 2016-08-23 |
| CA2851296C (en) | 2020-08-25 |
| WO2013067076A2 (en) | 2013-05-10 |
| ZA201403281B (en) | 2015-08-26 |
| IL232085A0 (en) | 2014-05-28 |
| EP2773758A2 (en) | 2014-09-10 |
| WO2013067076A3 (en) | 2013-07-04 |
| KR20140091683A (en) | 2014-07-22 |
| BR112014010769A2 (en) | 2018-08-07 |
| US20160362695A1 (en) | 2016-12-15 |
| MX356814B (en) | 2018-06-13 |
| AU2012332517B9 (en) | 2017-08-10 |
| CN103917647A (en) | 2014-07-09 |
| AU2012332517B2 (en) | 2017-04-06 |
| AU2012332517A1 (en) | 2014-04-24 |
| JP6118331B2 (en) | 2017-04-19 |
| JP2015501634A (en) | 2015-01-19 |
| IL232085B (en) | 2018-04-30 |
| CA2851296A1 (en) | 2013-05-10 |
| BR112014010769B1 (en) | 2021-08-03 |
| US9738896B2 (en) | 2017-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272539B (en) | Compositions and methods for immunotherapy | |
| EP2731446A4 (en) | Methods and compositions for consumables | |
| EP2731451A4 (en) | Methods and compositions for consumables | |
| ZA201306316B (en) | Methods and compositions for preparing noribogaine from voacangine | |
| EP2691397A4 (en) | Methods and compositions for preparing noribogaine from voacangine | |
| ZA201404399B (en) | Bio-pesticide methods and compositions | |
| EP2730619A4 (en) | Composition | |
| EP2741823A4 (en) | Methods and compositions for improving sperm functionality | |
| EP2692796A4 (en) | Composition | |
| PL2731963T3 (en) | Compositions and methods for immunomodulation | |
| ZA201403281B (en) | Methods and compositions for neuroprotection | |
| ZA201308892B (en) | Compositions and methods | |
| EP2766357A4 (en) | Meso-biliverdin compositions and methods | |
| EP2742139A4 (en) | Immunogenic compositions and methods therefor | |
| GB201108912D0 (en) | Composition | |
| GB201103964D0 (en) | Composition | |
| GB201115211D0 (en) | Composition | |
| EP2711011A4 (en) | Panaxadiol-containing composition | |
| SG2014010433A (en) | Stable compositions and methods for preparing the same | |
| GB201116416D0 (en) | Composition | |
| HK1174328A1 (en) | Methods and compositions for preparing noribogaine from voacangine | |
| GB201116340D0 (en) | Compositions and methods | |
| GB201121663D0 (en) | Process and compositions | |
| GB201110658D0 (en) | Improved process and compositions | |
| GB201100683D0 (en) | Compositions & methods |